NDC 65219-586 – Tyenne
Tocilizumab 162 mg/.9mL · Injection, Solution · Subcutaneous
Product NDC65219-586
Product details
- Brand name
- Tyenne
- Generic name
- Tocilizumab-aazg
- Labeler
- Fresenius Kabi USA, LLC
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- Marketing category
- BLA · BLA761275
- Marketed since
- July 1, 2024
- Listing expires
- December 31, 2027
- Pharmacologic class
- Interleukin-6 Receptor Antagonist
Active ingredients
- Tocilizumab 162 mg/.9mL
Package NDC codes (1)
| Package NDC | Description | Since |
|---|---|---|
| 65219-586-04 | 1 SYRINGE, GLASS in 1 CARTON (65219-586-04) / .9 mL in 1 SYRINGE, GLASS | Jul 1, 2024 |
Other Tyenne products
- 65219-584 Tocilizumab 162 mg/.9mL · Injection, Solution · Fresenius Kabi USA, LLC
- 65219-596 Tocilizumab 162 mg/.9mL · Injection, Solution · Fresenius Kabi USA, LLC
- 65219-598 Tocilizumab 162 mg/.9mL · Injection, Solution · Fresenius Kabi USA, LLC
- 65219-590 Tocilizumab 80 mg/4mL · Injection, Solution, Concentrate · Fresenius Kabi USA, LLC
- 65219-592 Tocilizumab 200 mg/10mL · Injection, Solution, Concentrate · Fresenius Kabi USA, LLC
- 65219-594 Tocilizumab 400 mg/20mL · Injection, Solution, Concentrate · Fresenius Kabi USA, LLC